{
  "id": 17076549,
  "title": "Ono's five failures; Lenz and Molecular Partners to lay off staff",
  "url": "https://urgent.news/2026/10/29/onos-five-failures-lenz-and-molecular-partners-to-lay-off-staff",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-29T15:08:22.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/onos-five-failures-lenz-and-molecular-partners-to-lay-off-staff/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Plus, news about GSK, Ascletis, BioMarin, Rigerna and Hisun. Ono Pharma’s endocannabinoid modulator flunks five trials: The biotech’s ONO-1110 did not meet the primary endpoint in five separate Phase 2 studies ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}